Newsroom

Lani Nguyen 4/8/24 Lani Nguyen 4/8/24

Model Medicines Reveals Breakthrough AI Discovery: RdRp Thumb-1, A Universal RNA Antiviral Target, and MDL-001, a Potent Inhibitor

Model Medicines is proud to announce the publication of our first preprint, "ChemPrint: An AI-Driven Framework for Enhanced Drug Discovery," now available on bioRxiv.

Lani Nguyen 3/28/24 Lani Nguyen 3/28/24

Model Medicines Publishes Groundbreaking Preprint on AI-Driven Drug Discovery

Model Medicines is proud to announce the publication of our first preprint, "ChemPrint: An AI-Driven Framework for Enhanced Drug Discovery," now available on bioRxiv.

Model Medicines’ CHEMprint™ AI/ML drug discovery platform successfully identified multiple drug candidates that were found to be active against SARS-CoV-2 replication in a live virus study in a human cell line at a hit rate of over 14%.

“AI and ML models... can significantly improve the efficacy of drug discovery.”

Arnab Chatterjee, Ph.D
Calibr at Scripps Research

“We are very pleased with the demonstrated potent antiviral activity of MDL-001.”

Davey Smith, MDUC
San Diego Health

“We are very excited to partner with Model Medicines on this important endeavor to identify novel therapeutics to treat the immediate threat of SARS-CoV-2 today and prepare for the pandemics of tomorrow.”

Sumit Chanda, Ph.D.
Sanford Burnham Prebys

“...a game-changer in the global fight against COVID-19.”

Adolfo Garcia-Sastre, Ph.D
Icahn School of Medicine at Mount Sinai